Company / Cash per Share
Trevi Therapeutics, Inc. Cash per Share History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$0.33
FY2024
5-year range
$0.20 / $2.49
FY2020-FY2024
Trend
+2.2%
vs FY2023
Sector context
#186 of 205
Health Care
What the data says
Among 205 Health Care companies, Trevi Therapeutics, Inc. is in the bottom 9% for cash per share. Improved from $0.20 to $0.33 over the past 2 years.
Based on SEC 10-K filings.
0.33 in FY2024 with a 5-year CAGR of -41.5%.
Improved from $0.20 to $0.33 over the past 2 years.
Health Care sector context is included.
Cash per Share over time
Growth rates
- 3-Year CAGR
- -40.8%
- 5-Year CAGR
- -41.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 205This company $0.33 Sector average $72.93
▼
-99.5% below sector average
Key checks
Key Insights
- In FY2024, cash per share increased 2.2% year-over-year.
- Ranks #186 out of 205 companies in the Health Care sector.
- Peak cash per share was recorded in FY2018.
- Lowest cash per share in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.91 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $0.33 | +2.2% |
| FY2023 | $0.33 | +67.7% |
| FY2022 | $0.20 | -87.9% |
| FY2021 | $1.61 | -35.3% |
| FY2020 | $2.49 | -49.0% |
| FY2019 | $4.88 | -70.3% |
| FY2018 | $16.46 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026